Description
The fiscal year 2026 (FY26) Traumatic Brain Injury and Psychological Health Research Program (TBIPHRP) Clinical Trial Award (CTA) intends to support clinical trials with the potential to have a significant impact on psychological health conditions and/or traumatic brain injury (TBI) through clinical applications, including health care products, technologies and/or practice guidelines. The program seeks to fund research that understands, prevents and treats psychological health conditions and/or traumatic brain injuries that accelerates solutions to improve the health, well-being and health care of Service Members, DOW beneficiaries, Veterans and the American Public.
• Clinical trials may be designed to evaluate a wide range of interventions, including new drugs, biologics, medical devices, diagnostics, therapies and behavioral health strategies.
• Preliminary data are required.
• The inclusion of community-based participatory research (CBPR) approaches is required.
• The CTA offers funding for two Research Levels: Research Level 1 supports proof-of-principle pilot studies, as well as phase 1 and phase 2 clinical trials, while Research Level 2 supports larger-scale and advanced clinical trials that evaluate effectiveness in relevant patient populations.